tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lepu Biopharma Completes H Share Full Circulation to Enhance Market Presence

Story Highlights
Lepu Biopharma Completes H Share Full Circulation to Enhance Market Presence

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.

Lepu Biopharma Co., Ltd. has successfully completed the conversion of 54,268,364 unlisted shares into H shares, marking the completion of its H share full circulation. This strategic move enhances the company’s market presence by increasing the liquidity of its shares, as the converted H shares will be listed on the Stock Exchange starting July 22, 2025. The company’s share capital structure now consists entirely of H shares, which could potentially attract more investors and improve stakeholder confidence.

More about Lepu Biopharma Co. Ltd. Class H

Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapeutics, particularly in the field of oncology, and is listed on the Hong Kong Stock Exchange.

Average Trading Volume: 26,377,316

Technical Sentiment Signal: Buy

Current Market Cap: HK$14.33B

For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1